Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊)

Li Li; Xiao-jin Zhang; Yu Lan; Le Xu; Xue-zhi Zhang; Hua-hong Wang

doi:10.1007/s11655-010-0023-1

Your Location：

Home >

Browse articles >

Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊)

OriginalPaper | Updated：2021-08-27

- Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊)
- Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊)
- 中国结合医学杂志（英文版） 2010年16卷第1期页码：23-27
- Affiliations：
  
  1. Gastroenterology Department, Beijing Jishuitan Hospital,Beijing,China
  2. Beijing Hospital,Beijing,China
  3. The First Hospital Affiliated to Peking University,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-010-0023-1
  中图分类号：
- 纸质出版日期：2010，
  
  网络出版日期：2010-2-4，
Scan for full text
Li, L., Zhang, Xj., Lan, Y. et al. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊)., Chin. J. Integr. Med. 16, 23–27 (2010). https://doi.org/10.1007/s11655-010-0023-1

Li Li, Xiao-jin Zhang, Yu Lan, et al. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊)[J]. Chinese Journal of Integrative Medicine, 2010,16(1):23-27.
Li, L., Zhang, Xj., Lan, Y. et al. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊)., Chin. J. Integr. Med. 16, 23–27 (2010). https://doi.org/10.1007/s11655-010-0023-1 DOI：

Li Li, Xiao-jin Zhang, Yu Lan, et al. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊)[J]. Chinese Journal of Integrative Medicine, 2010,16(1):23-27. DOI： 10.1007/s11655-010-0023-1.

摘要

To observe the therapeutic effect and safety of Qianggan Capsule (强肝胶囊

QGC) in treating non-alcoholic fatty liver disease (NAFLD)

using polyene phosphatidylcholine capsule (PPC) as a reference. Eighty-eight patients with NAFLD were randomly assigned to two groups

45 in the treatment group treated with QGC and 43 in the control group treated with PPC. The course of treatment lasted for 6 months. Changes in liver function

blood lipids

and iconographic indexes before and after treatment were observed

and clinical efficacy was evaluated. In the treatment group

alanine aminotransferase (ALT) was lowered significantly from 56.02±32.59 IU/L before treatment to 38.27±22.68 IU/L after treatment

and CT liver/spleen ratio significantly increased from 0.69±0.18 to 0.91±0.25

showing statistical significance (P<0.05); in contrast

the corresponding changes of the two indexes in the control group were 56.56±26.33 IU/L to 49.67±26.22 IU/L

and 0.66±0.20 to 0.75±0.24

respectively

the pre-post treatment difference showing insignificant difference (P>0.05). No severe adverse reactions occurred during the whole treatment course. QGC is an effective and safe remedy for the treatment of NAFLD.

Abstract

To observe the therapeutic effect and safety of Qianggan Capsule (强肝胶囊

QGC) in treating non-alcoholic fatty liver disease (NAFLD)

using polyene phosphatidylcholine capsule (PPC) as a reference. Eighty-eight patients with NAFLD were randomly assigned to two groups

45 in the treatment group treated with QGC and 43 in the control group treated with PPC. The course of treatment lasted for 6 months. Changes in liver function

blood lipids

and iconographic indexes before and after treatment were observed

and clinical efficacy was evaluated. In the treatment group

alanine aminotransferase (ALT) was lowered significantly from 56.02±32.59 IU/L before treatment to 38.27±22.68 IU/L after treatment

and CT liver/spleen ratio significantly increased from 0.69±0.18 to 0.91±0.25

showing statistical significance (P<0.05); in contrast

the corresponding changes of the two indexes in the control group were 56.56±26.33 IU/L to 49.67±26.22 IU/L

and 0.66±0.20 to 0.75±0.24

respectively

关键词

non-alcoholic fatty liver diseaseChinese medicinal therapyQianggan Capsulepolyene phosphatidylcholine capsule

Keywords

non-alcoholic fatty liver diseaseChinese medicinal therapyQianggan Capsulepolyene phosphatidylcholine capsule

references

Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003;38:1008–1017.

Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Society of Hepatology, Chinese Medical Association. Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases. Chin J Hepatol (Chin) 2006;14:161–163.

Li F, Fan JG, Cai XB. Non-alcoholic fatty liver disease promotes the development of metabolic abnormalities. Chin Hepatol 2006;11:7–11.

Zhang L, Jia JD. Pathogenesis of non-alcoholic fatty liver and pharmacotherapy. Clin Med J (Chin) 2005;3(4):21–23.

Zeng MD. Stress on research of nonalcoholic fatty liver disease. Chin J Hepatol (Chin) 2003;11(2):69–70.

Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003;17:977–986.

Cheng CX, Peng JH, Zhao YD, Yin JP. Ultrasound and CT quantitative diagnosis of diffuse fatty infiltration of the liver. Chin Imaging J Integr Tradit West Med (Chin) 2006;4:440–441.

Zou Q, Wang B, Li LX, Lu SJ, Sun XH. Single-energy CT quantitative diagnosis of fatty liver: an experimental study. J Clin Radiol (Chin) 2002;21:150–154.

Zeng BH, Huang DZ, Fan LY. Clinical observation of the treatment on fatty liver by Essentiale. Pract Clin J Integr Tradit Chin West Med (Chin) 2006;6(10):25–26.

Ding XC, Ma LN, Zhang X. Influence of Qianggan Capsule on indexes of hepatic fibrosis in patients of chronic liver disease. Chin J Integr Tradit West Med Dig (Chin) 2003;11:351.

FULL TEXT LINK

More>

浏览量

393

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Ping-tang Recipe (平糖方) improves insulin resistance and attenuates hepatic steatosis in high-fat diet-induced obese rats

Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats

Effect of Tianhuang Granule (田黄冲剂) on intracranial pressure and serum matrix metalloproteinase-9 in patients with acute cerebral hemorrhage

Clinically controlled study on children’s infectious mononucleosis treated by Chinese medicine